Life diversity can now be clearly explored with the next-generation DNA sequencing technology, allowing the discovery of genetic variants among individuals, patients and tumors. However, beyond causal mutations catalog completion, systems medicine is essential to link genotype to phenotypic cancer diversity towards personalized medicine. Despite advances with traditional single genes molecular research, including rare mutations in BRCA1/2 and CDH1 for primary prevention and trastuzumab for treating HER2-overexpressing breast and gastric tumors, overall, treatment failure and death rates are still alarmingly high. Revolution in sequencing reveals that, now both a huge number and widespread variability of driver mutations, including single-nucleotide polymorphisms, genomic rearrangements and copy-number changes involved in breast cancer development. All these genetic alterations result in a heterogeneous deregulation of signaling pathways, including EGFR, HER2, VEGF, Wnt/Notch, TGF and others.Cancer initiation, progression and metastases are driven by complex molecular networks rather than linear genotype-phenotype relationship. Therefore, clinical expectations by traditional molecular research strategies targeting single genes and single signaling pathways are likely minimal. This review discusses the necessity of molecular networks modeling to understand complex gene-gene, protein-protein and gene-environment interactions. Moreover, the potential of systems clinico-biological approaches to predict intracellular signaling pathways components networks and cancer heterogeneous cells within an individual tumor is described. A flowchart specific for three steps in cancer evolution separately tumorigenesis, early-stage and advanced-stage breast cancer is presented. Using reverse engineering starting with the integration of available established clinical, environmental, treatment and oncological outcomes (survival and death) data and then the still incomplete but progressively accumulating genotypic data into computational networks modeling may lead to bionetworks-based discovery of robust biomarkers and highly effective cancer drugs targets.
Introduction
Cancer is a highly complex and heterogeneous disease. [1] [2] [3] [4] [5] Cancer initiation, progression and metastases are driven by mutations. These DNA changes, mostly somatic, but also inherited, accumulating deregulated signaling pathways that cause cancer development and evolution. 4 Epigenetic changes-chemical modifications of DNA and its associated proteins may also contribute to tumorigenesis through gene expression deregulation. 6, 7 Over the past 3 years, massively parallel DNA sequencing platforms have become widely available. As the cost of reading and writing DNA in the last decade has dropped by a million-fold, in the next few years less than $1000 will be required for a whole-genome sequencing; international personal genomics projects are now underway to explore the diversity of life and understand why each of us are unique. The '1000 genomes' project, the International Cancer Genome Consortium (see http://www.icgc.org/ home) 5 and the International Human Epigenome Consortium, 6 will deliver information about health and disease as it progresses, particularly about intractable diseases, such as cancer. 6 Eight human genomes and several cancer genome sequences for individual patients with acute myeloid leukemia, 8, 9 lung cancer, 10 melanoma 11 and breast cancer 12 have been most recently reported. Beyond point mutations, base substitutions, insertions or deletions of small or large segments of DNA -rearrangements, DNA broken and rejoined to a DNA segment from elsewhere in the genome and copy number changes are implicated in cancer. 5 Indeed, using new 'paired-end' sequencing technologies, a latest study has shown more genomic rearrangements than previously recognized. Most of them were tandem duplications and remarkably, common in some breast cancers, but essentially absent from others and may reflect a novel mutator phenotype. 13 These current findings [5] [6] [7] [8] [9] [10] [11] [12] [13] and evidence from recent extensive genetic studies, 3, 4 reveal the high complexity and variability of genetic bases of cancer.
This cancer heterogeneity underlines the importance of personalized medicine, one of the biggest biomedical challenges. To achieve this goal, two steps are essential. First, to be completed the catalog of driver mutations. To obtain such a catalog, for example mutations and genes of breast cancer, many sequencing studies with large numbers of patients' samples will be required because the widespread of the genetic variability. The second goal, which is to understand how the cancer genomes and individual tumors function as whole biological systems, is much more complicated. There is a need to acquire insights into how intracellular signaling pathways network is deregulated in cancer 14 and to understand the interactions among heterogeneous cancer cells with different treatment response within an individual tumor. [1] [2] [3] [4] Similarly, exploration of tumor microenvironment 2, 15 and of a more global approach to link individual tumors with their multiple host variables, including heritable causal mutations, environmental exposures and lifestyle, are of fundamental importance and represent systems medicine approaches. 16 This article provides an overview for the advances of standard single-gene molecular research and how current substantial limitations might be overcome. Given the widespread genetic variability and the molecular interactions complexity of breast cancer and gastric cancer, it is discussed how next-generation of molecular networks scenarios [17] [18] [19] might lead to bionetworks-based discovery of biomarkers and biological agents.
Breast and gastric cancer
With nearly 2 million new diagnoses and over 1.2 million deaths each year worldwide, 20 breast cancer and gastric cancer are a major health problem. In the United States, breast cancer is and will probably continue to be the most common malignancy among females, whereas gastric cancer incidence has dramatically been reduced in the United States, but its global incidence and mortality still remain alarmingly high. 21 The current highest mortality rates in non-early stages reveal that despite intensive research efforts and advances with surgery, radiotherapy and systemic treatment death rates improvement is modest and very slow over the last decade. 21 Systemic treatment with chemotherapy has improved survival and saved the lives of many patients with cancer. 22 Particularly for breast cancer, the addition of tamoxifen to chemotherapy as a systemic treatment in endocrine-responsive, estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive patients has saved the lives of a substantial proportion of women with a potentially curable stage of disease. 23 Studies with longer than 5-year survival results are important for quality assessment of treatment effect on oncological outcomes. The 15-year survival results of a largescale meta-analysis prove that the risk of recurrence and death is still very high; approximately 60% of patients with an earlystage breast cancer recur at 15 years after surgery and adjuvant multimodal therapy. 23 Similarly, in gastric cancer, the 15-year survival results of the Dutch trial, including stage I-III patients, have shown a 37% death rate because of the recurrence after adequate D2 surgery alone. 24 However, the failure treatment rates for the most common stages II and III in the Western world are much higher. Despite adjuvant perioperative chemotherapy for stages II and III, the overall treatment failure rate measured as 5-year recurrence or death rate was over 60% in a Western randomized controlled trial (RCT). 25 Similarly poor are the results from the USA despite standardization of adjuvant chemoradiotherapy. 26 The reasons for the higher corresponding rates of 60% or more 5-year survival rate in Japan 27 have not yet been clarified although the extend of lymphadenectomy may have a crucial role in this different outcome. 28 Although adjuvant systemic chemotherapy significantly improves survival, the net absolute survival benefit is less than 15%. In the metastatic, stage IV setting, the mean survival is B26 months for breast cancer and B12 months for gastric cancer despite major efforts, funding and development and use of newer chemotherapeutic agents combinations. 22 How could survival substantially be prolonged in the metastatic setting and cure rates be improved in the adjuvant setting? Arguments in favor and against standard molecular biology and sophisticated systems approaches are discussed.
importantly from a patient perspective, some of these have been translated into clinical practice in both the prevention and treatment setting.
Primary prevention
The discovery of BRCA1 and BRCA2 (BRCA) 29, 30 33 Prophylactic surgery or closed surveillance can save the lives of these high-risk persons.
32,33
Limitations Table 1 summarizes the limitations of genetic testing in the prevention setting. Despite basic science advances and the advent of genome-wide association studies, for the vast majority of people in the general population, accurate prediction of a person's cancer risk is elusive. 34 Indeed, these inherited mutations are very rare in the general population and mutation carriers account for 3-10% only of these cancer types. The predictive accuracy among persons with positive genetic testing at the age of 50 years is less than 50% and ultimately 25% of the mutation carriers in BRCA1/2 or CDH1 genes will never develop breast or gastric cancer, respectively. This uncertainty challenges a tailored surgical or medical preventive intervention in carriers of these mutations with outsized cancer risk.
Present generation of targeted therapy
It was only recently that the concept of biological agents has been incorporated into the pharmaceutical industry, approximately 50 years after the discovery of the epidermal growth factor (EGF or ERB) and its receptor (EGFR or ERBB). 35 Targeting only cancer cells, but not healthy cells, when using biologics could dramatically improve the poor outcomes of cancer patients, while maintaining very low adverse effects profiles. Now, as multiple sets of data from RCTs have been made available, how optimistic have we been?
EGFR and trastuzumab
The Erbb family has a crucial part in the development and evolution of cancer. This receptors family consists of four closely related type 1 transmembrane tyrosine kinase receptors: EGFR (or HER1), ERBB2 (HER2), ERBB3 (HER3) and ERBB4 (HER4). In contrast to HER1 and HER2, HER3 does not have tyrosine kinase activity. Each receptor comprises an extracellular domain at which ligand binding occurs, an a-helical transmembrane segment and an intracellular protein tyrosine kinase domain. Ligand binding to these EGF family receptors phosphorylates and activates a complex intracellular signaling pathways network that controls a range of cellular processes, including proliferation, angiogenesis, cell cycle, survival and apoptosis ( Figure 1a ).
36
HER2 amplification and overexpression has a central role in initiation, progression and metastasis of some common cancers, including breast cancer and gastric cancer. [35] [36] [37] [38] HER2 status has been recognized as an important prognostic factor. Patients with breast cancer or gastric cancer and HER2-positive disease have significantly worse survival than those with HER2-negative tumors. [35] [36] [37] [38] Thus, this pivotal receptor is a potential therapeutic target.
Trastuzumab, a monoclonal antibody (Figure 1b) , the binding of which to HER2 receptors, inhibits HER2 signaling pathway activity in tumor cells overexpressing HER2. In the metastatic setting, a previous RCT for breast cancer 37 and a most recent international phase-III RCT for gastric cancer 38 have provided evidence for the safety and efficiency of trastuzumab added to chemotherapy to prolong significantly overall survival (OS) in patients with these two major cancer types and HER2-positive tumors. For advanced, metastatic or recurrent HER2-positive gastric cancer, trastuzumab-based systemic treatment with chemotherapy has become a new standard of care. 39, 40 In the adjuvant setting, trastuzumab for early-stage breast cancer represents the triumph of bench-to-bedside molecular research. 41, 42 Indeed, potential clinical success at this setting can save the lives of thousands of patients with nonmetastatic disease. Five RCTs in HER2-positive early-stage breast cancer comparing adjuvant systemic chemotherapy with and without trastuzumab in 13 493 patients have been reported. [43] [44] [45] [46] [47] [48] [49] All, these studies have demonstrated the 
Trastuzumab and beyond
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superiority of trastuzumab in both disease-free survival and OS. An updated meta-analysis has showed a significant reduction of risks of recurrence by 38% and death by 34%. 50 Table 2 summarizes adverse effects and resistance to adjuvant treatment of breast cancer with trastuzumab. These limitations suggest the need for novel cancer research strategies. Intrinsic and acquired resistance is the biggest challenge. No response to trastuzumab has been reported in HER2-negative patients, who account for 475% of all breast cancers, whereas the net response rate among HER2-positive patients with breast cancer is less than 15%. Administration of trastuzumab was associated with increased risks for congestive heart failure, left ventricular ejection fraction decline and central nervous system metastasis as the first recurrence event. In addition, given the short-term followup it is unclear whether trastuzumab may have a long-term efficacy leading to cure or it has simply only a delayingrecurrence occurrence effect. From a general point of view for all solid tumors, the present generation of biologics targeting a single component of a signaling pathway has substantial limitations. Biological agents include two major groups of drugs: monoclonal antibodies and small molecule tyrosine kinase inhibitors. The mechanisms of action of these two agents' GSK3b, glycogen synthase kinase 3b; NF-kB, nuclear factor-kB; PDK1, pyruvate dehydrogenase kinase 1; PIP2, phosphatidylinositol biphosphate; PIP3, phosphatidylinositol triphosphate.
Trastuzumab limitations
categories differ. For example, the monoclonal antibodies cetuximab or panitumab used in the treatment of metastatic colorectal cancer binding to extracellular portion of EGFR block the ligand-receptor dimerization inhibiting signal transduction from cell outside the nucleus. By contrast, the EGFR tyrosine kinase inhibitors, erlotinib and gefitinib, developed for the treatment of non-small-cell lung cancer and other tumors compete reversibly with ATP to bind to the intracellular domain of EGFR thus, inhibit EGFR autophosphorylation and downstream signaling. 14, 36 Despite positive results with phase I-II studies, phase-III RCTs have provided negative results. 51, 52 The initial overenthusiasm could not be confirmed by comparative-effectiveness research essential for the translation of new agents into clinical practice. 53, 54 After this failure assessment, efforts have focused on tumor genotyping for the identification of mutations that might guide patients' selection for anti-EGFR treatment. Indeed, phase III trials have demonstrated a significant benefit in survival among patients with a specific mutations status. However, even with this genotyping-based patient selection, there are limitations. For example, phase-III RCTs showed that the treatment with cetuximab of patients with metastatic colorectal cancer without KRAS mutations 55 or the treatment with gefitinib of patients with advanced EGFR mutations non-small-cell lung cancer, 55, 56 was associated with a benefit only in progression-free survival, but not in OS. However, evident cancer genetic heterogeneity even within individual tumors with variability of cancer cells population in therapeutic response 57 with anti-EGFR and anti-VEGF agents, 52, 58, 59 arises valid concerns for the use of progression-free survival as a robust marker of treatment response. Complete eradication of all cancers cells is better measured with OS improvement.
New markers tested in clinical trials
Currently, approximately 30% of patients with early-stage, node-negative breast cancer are receiving unnecessary adjuvant chemotherapy and some other patients miss a useful chemotherapy treatment. To improve patients selection on the basis of the standard clinicopathological features, including age, tumor size, histological grade and node status and molecular markers, such as hormone receptor (ER/PR) status and HER2 status, two categories of new markers have been developed and reached the level of evaluation in phase-III RCTs. Micrometastases and isolated tumor cells in axillary lymph nodes and multigene assays.
Micrometastases and isolated tumor cells
As a next step of traditional node metastases with tumor deposit 42 mm (N1 disease), micrometastases (0.2 mm4 N1mi o2 mm) and isolated tumor cells (N0[i] o0.2 mm) in sentinel and non-sentinel axillary lymph nodes have been recently suggested as prognostic markers. Although a largescale recent study has reported that women with early, node-negative (N0) breast cancer, but micrometastases and/ or isolated tumor cells in sentinel and non-sentinel axillary lymph nodes were benefited from adjuvant chemotherapy, 60 methodological flaws of this retrospective study suggest the need for awaiting results of Phase-III RCTs for definitive conclusions. 61 
Multigene assays
The advent of high-throughput sequencing technology has revolutionized screening approaches allowing the identification of profiling expression of hundreds of genes at a time. Several gene-expression profiling studies using the first generation of microarrays have resulted in the development of both a molecular classification of breast cancer and multigene assays. 62 It was thought that such a multigene approach could lead to more individualized therapeutic decisions in a mean of personalized medicine.
Among many multigene assays developed and published to have prognostic or predictive value for many solid tumors, including breast cancer, two gene signatures have the most rapid progress. The 21-gene assay and the 70-gene signature have already been commercialized. The 21-gene Recurrence Score was developed for identifying high-risk patients of distant recurrence among those with nodenegative, ER-positive early breast cancer. 63 It is believed that this 21-gene assay (Oncotype DX) may improve decision on the addition of adjuvant chemotherapy to tamoxifen among women with ER-positive, node-negative early breast cancer. The 70-gene signature developed in the Netherlands for avoiding chemotherapy in early, node-negative breast cancer has been approved by the Food and Drug Administration. 64 However, there has been scepticism for both, the original studies used for the development of these genetic tools and the subsequent retrospective validation studies, because of methodological flaws. [65] [66] [67] Given the emerging evidence for the highly complex heterogeneity of cancer, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] it is rather an oversimplification and naive to predict the clinical value of these genetic tests before the results of underway Phase-III RCTs in the United States (Trial Assigning Individual Option for Treatment (AILORx)) and in Europe (Microarray in Node-Negative Disease Avoids Chemotherapy (MINDACT) trial) became available. 65 Gene expression signatures based on the first generation of microarrays have substantial limitations for incorporation into clinical practice [65] [66] [67] [68] and hope has been moved to the next generation of DNA microarrays, including microRNA arrays. 62 
Future personalized medicine perspectives
To increase the efficacy and safety of cancer therapeutics, data, information and evidence accumulating suggest an urgent need for the development of biomarkers to tailor the best possible treatment to the right patient at the right time. 69 These biomarkers are of paramount importance to improve response rates and reduce adverse effects for the currently available agents. Similarly, new therapeutics strategies consider this concept of the development of both novel drugs and biomarkers as predictors of response for patient selection. 69 The era of personalized medicine based on new sequencing technologies for genotyping and identifying cancer genomes variants responsible for response or resistance is here. 70, 71 But, yet myriad problems exist for achieving major clinical applications of personalized medicine. [71] [72] [73] To overcome resistance to breast treatment, various strategies have been developed. For example, there are currently more than 30 cancer stem cells R&D programmes in progress, around 50% of which are at Phase I or beyond. 74 But most pharmaceutical and biotechnology companies and academic research institutions have been focussing on agents that target HER2, EGFR and most Table 3 summarizes preclinical and clinical studies that evaluate these agents. Further efforts are underway to evaluate potential combinations that target multiple or pivotal players in oncogenic signaling cascades. For example, promising results have been reported for PI3K hyperactivation-mediated resistance to lapatinib and trastuzumab, which was overcome by the addition of a dual inhibitor of both mToR and PI3K. 74 Although it may present a more rational approach, the current evidence for complexity of interacting cancer cells and signaling pathways suggest the need for networks approaches and global understanding of cancer genomes.
Cancer heterogeneity and complexity-based direction
Emerging solid evidence by using new sequencing technologies reveals that cancer nature is much more complicated than we imagined. Somatic and heritable mutations drive tumor development, growth and metastasis through deregulation of signaling pathways. Apart from EGFR and VEGF pathways, several other downstream pathways, including Wnt/Notch, Hedgehog, TGF and others may have a crucial role in cancer initiation and evolution. Available evidence from both low-throughput and high-throughput analysis suggests that presently B400 cancer genes (http://www. sanger.ac.uk/genetics/CGP/Census/) have been identified with estimates to indicate a huge number of genetic and genomic alterations.
Next-generation DNA sequencing technologies promise to identify all these DNA changes and improve the understanding of cancer genes function. Indeed, with a trend towards faster and cheaper whole-or partial-targeted genome sequencing, genome-wide RNA, serial analysis of gene expression, microRNAs, protein-DNA interactions and comprehensive analyses of transcriptomes and interactomes 70 important insights into molecular mechanisms underlying cancer development and metastasis will emerge. However, the distance from this general and imprecise statement to reach clinical success with robust biomarkers and biologics is huge. Multiple problems await solution.
Challenging in moving forward
If we accept the variability and network complexity of cancer, then single genes molecular research has major limitations in the discovery of druggable targets. These limitations in both prevention and treatment setting are showed in Tables 1 and 2 , respectively. A rational strategy includes two major challenges, the completion of mutations catalog and the understanding of an individual's tumor whole systems function.
Completing cancer mutations catalog
Despite advances with massively parallel sequencing technologies and decreasing costs, the way to complete a comprehensive catalog of genetic alterations in breast cancer and gastric cancer is long with multiple challenges.
First, these new sequencing techniques can primarily identify point mutations, including base substitutions and small insertions or deletions. The first nearly-complete genomes sequencing in a patient with lobular, ER-positive breast cancer has been recently reported. 12 Hundreds of patient's samples for each classification category, which is currently used in clinical practice, will be required to be completely sequenced in order to obtain a full catalog of point mutations. However, given that more than 100 000 000 000 base pairs of DNA sequence will probably be required to identify causal single-nucleotide polymorphisms (SNPs) that imply at least 20-fold sequence coverage of the cancer genome, that increases the costs.
Second, beyond point mutations, genomic rearrangements and copy number changes also have a crucial role in cancer and thus these should also be identified. Yet, the techniques for reliable results have not been standardized. For example, most recently, Stephens and colleagues 13 using a new technique have mapped the chromosome rearrangements in human breast cancers at high resolution. They found more rearrangements than previously recognized, and tandem duplications were remarkably common in some breast cancers but essentially absent from others, suggesting also potential breast cancer phenotypic diversity related to rearrangements. Presently, using similarly high-resolution analysis (Affymetrix 250K Sty I array), Beroukhim et al. 75 analyzed 3131 cancer specimens for identifying somatic copy-number alterations. Among 243 breast cancers and 23 gastric cancers, the genomic landscape showed an average of B75 somatic copy-number alterations of which there were B45 amplifications and B30 deletions. 75 Third, mitochondrial DNA (mtDNA) mutations, beyond the nuclear DNA mutations reported above, may improve understanding of the cancer nature. Indeed, providing insights into the nature and variability of mtDNA sequences may have implications for cancer biomarker development. A most recent study by the Vogelstein team 76 using massively parallel sequencing-by-synthesis approaches found widespread heterogeneity (heteroplasmy) in the mtDNA of normal human cells and cancer cells. Moreover, the frequency of heteroplasmic variants varied considerably between different tissues in the same individual. In addition to the variants identified in normal tissues, cancer cells harboured further homoplasmic and heteroplasmic mutations that could also be detected in patient plasma. Given the higher concentration of mutant mtDNA molecules in the plasma than that of the mutant nuclear mutations, mtDNA mutations could reliably be used as tumor-specific biomarkers. 76 In summary, to obtain a complete mutations catalog, new studies using massively parallel sequencing approaches with large patients' samples will be required given breast cancer and gastric cancer variability. Challenges include distinguishing of all these alterations into somatic and inherited, as well as into causal (driver) and non-causal (passengers) mutations. 5 
Bionetworks towards genotype-phenotype MAP exploration
Individual human cancers are either homogenous tumors or they contain a complex mixture of cancer-interacting cells with variability of mutations of their cancer genomes. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] In contrast to good prognosis of patients with sensitive homogenous tumors, mostly in early stages, mixture tumors containing aggressive, non-sensitive cancer cells to current treatment, mostly diagnosed at advanced-stage disease, have a poor prognosis. 3, 4, 18, 57, 71 Even if future studies reach the completion of mutations and genes catalog for major cancers, such as breast or gastric tumors, the bigger challenge will be to understand how an individual tumor functions within a certain patient as a complex whole clinico-biological system. 18 Such an in-depth analysis requires advances in systems biology, medicine and oncology. [16] [17] [18] [19] 57 Rational steps towards this direction include exploration of the kind of cells within an individual mixture tumor, their interactions and the impact of the individual host that is strongly related with the environment and lifestyle of this individual person. Genetic ancestry and the magnitude-small, moderate, high of genetic susceptibility to a specific cancer type also has a crucial role in cancer initiation and evolution. Therefore, completing the catalog of somatic and inherited mutations represents a substantial progress, but a part only in the puzzle of cancer nature. In most cases, cancer development and progression is driven by complex genes-genes and genetic-environmental factors interactions. The inference of these networks defines the cancer phenotype rather than a simple linear link between a single mutated gene and cancer. Therefore, sophisticated systems medicine approaches 16 will be required to acquire insight into how genotype-phenotype operates and how using network modeling could predict the oncological outcome, that is, cancer development, metastatic recurrence/death or cure after a specific therapy.
17-19
Tumor microenvironment and metastasis An individual primary breast tumor or gastric tumor is consisted from cancer cells and non-cancer cells termed as stroma or microenvironment comprising numerous cells, including endothelial cells of the blood and lymphatic circulation, stromal fibroblasts and a variety of bone marrow-derived cell. The development of cancer cells from normal cells (tumorigenesis). This microenvironment influences tumor growth at the primary site and development of occult micrometastases or clinically evident metastases at distant sites (secondary tumors). 15 Therefore, consideration of the interactions between cancer cells and stromal cells is also required during the designing bionetworks strategies. [15] [16] [17] [18] [19] Bionetworks for breast cancer Figure 2 delineates a flowchart towards a new horizon of networks-based identification of key targets for breast cancer. For both, research and clinical reasons a classification into tumorigenesis, early-stage disease and advancedstage cancer is meaningful. Differences in the number of genetic alterations, the degree of the impact of environmental exposures, treatment intervention and prognosis in each category make, nearly essential, a separate research strategy if we aim at achieving clinical implications.
Tumorigenesis-based tailored prevention
It is thought that normal breast epithelial cells are converted into cancer cells as a result of genetic and environmental factors. Therefore, efforts to identify these two risk factors categories have been performed. Many lifestyle and environmental risk factors for breast cancer have been identified (age at menarche/menopause, parity, age of first and subsequent pregnancies, breastfeeding, exogenous estrogen use, body mass index, height and alcohol consumption). 77 Several genetic risk variants have been identified using conventional low-throughput sequencing. 3 On the basis of the high-throughput sequencing technologies and biochips developed, genome-wide association studies have identified many SNPs, which, however, confer a small breast cancer risk. 78 The concept, therefore, to combine traditional risk factors and recently identified genetic variants (SNPs) for women's risk stratification appear promising. A latest study involving 5590 case subjects with breast cancer and 5998 control subjects, the addition of information on 10 newly identified genetic variants (SNPs) to a standard clinical breast-cancer risk model (Gail model, including reproductive history, family history of close relatives with breast cancer and previous breast biopsies) provided disappointing results without significant predictive power of SNPs. 79 These current negative results in women's personalizedrisk-based prediction for primary prevention are not surprising. Efforts to risk prediction on the basis of an incomplete breast cancer mutations catalog and without considering complex genes-genes and genes-environment interactions will likely have modest clinical success. The magnitude of complexity and challenge is revealed by the running Breakthrough Generations, a study into the genetic and environmental causes of breast cancer that has recruited 100 000 British women and has received d12-million in start-up funding from the Institute of Cancer Research and the Breakthrough Breast Cancer charity. The plan is to collect detailed health information over the next 40 years to improve understanding of the causes and prevention of cancer.
Alternatively, instead of waiting for several decades, predictive network modeling might have faster clinical implications. Given the nonlinear relationship between causal mutations and breast cancer phenotypes computations network strategies are required to predict cancer development among individual women in the general population. Women with strong family history and highrisk heritable BRCA mutations represent a distinct group and should be studied separately. Two sets of data required for networks integration models: genetics and clinical data. Yet major challenge is the threshold of the number of causal mutations required for conversion of normal cells into cancer cells. Earlier estimates and experimental data have suggested roughly seven 'hits' or five to sixmutated genes, 80, 81 but recent reports considering latest sequencing data show that this number is higher with approximately at least 20 genes to be involved in tumorigenesis. 82 As cheaper sequencing techniques became available many more causal mutations, including SNPs, rearrangements and copy-number changes, will be identified by ongoing and new studies.
Many traditional factors, including age, reproductive factors, family history, breast biopsies and breast density on mammographic screening have been identified as standard risk factors for breast cancer. Although detailed information on all these variables (for example, age at menarche, number of children, breastfeeding, exogenous estrogen use, body mass index, height, alcohol consumption, diet and several other lifestyle factors), is unable to identify high-risk women, combination with genetic factors may increase this predictive potential. Integrating all these empirical data along with emerging next-generation sequencing platforms data into computational-mathematical model may lead to the identification of high-risk women in the general population. Given the long time required to complete the mutation catalog of breast carcinogenesis, using reverse engineering methods integrating first the completed traditional data and then the incomplete, but progressively accumulating genetics data, the time needed for networks-based prediction of high-risk women may be shorter than awaiting the full gene catalog to be completed.
Early-stage breast cancer
Despite advances with endocrine therapy for hormonereceptor-positive patients and trastuzumab for HER2-positive tumor, many of these patients recur because of resistance and die. 23, 50, 83, 84 No endocrine therapy can be used for one-third of patients who have hormone-receptornegative tumor and two-thirds who have HER2-negative tumor cannot benefit from trastuzumab, as it is not effective in these tumors. As a result, these patients can receive only adjuvant chemotherapy, with an overall, poor prognosis.
One of the most promising R&D strategies to overcome this substantial resistance to current treatment is the field of molecular networks. Locoregional and distant recurrences are driven by complex genetic, molecular and cellular interactions rather than a simple linear genotype-phenotype relationship. Therefore, understanding of these networks could be considered as nearly essential to predict recurrence risk and therapeutic response.
Prospective studies to link oncological outcomes (recurrence/death vs no recurrence/cure) with somatic causal mutations are the most rational scientific way for identifying robust biomarkers and effective drugs. But such an approach will require several decades for completing the mutation catalog of point mutations, genomic rearrangements and copy-number changes and subsequently to await 5-10 years follow-up results to define causal responsible mutations for treatment failure. Figure 2 Flowchart on bionetworks-based approaches to discover key cancer targets (biomarkers/biological agents) adapted to genetic bases of cancer, heterogeneity and complex interactions.
An attractive alternative is bionetworks approach. To predict genotype-phenotype map, both genotypic and phenotypic data are required. Currently, high-quality clinical (phenotypic) data are available from large-scale RCTs and meta-analyses. With the general term, clinical data are included myriad variables. These are clinicopathological features (age, tumor size, node status and histological grade), standard molecular markers (ER/PR/HER2 status), environmental-lifestyle factors some of which may continue to affect recurrence, treatment (surgery, radiotherapy, chemotherapy, endocrine therapy, trastuzumab, toxicity and adverse effects) and patients outcome. Despite the large number of variables, short-and longterm follow-up results define two only events, that is, recurrence or death and survival without recurrence. The task will be to link these outcomes events with the inference of clinical and genetic interactions.
Yet, breast cancer genotypic data are incomplete, but these are rapidly accumulating with the next-generation sequencing platforms for point mutations and copy-number changes and new techniques for rearrangements identification.
Therefore, using reverse engineering methods to build network modeling starting with the integration of phenotypic (clinical) data completely available appears a powerful strategy. Further integration of genetics data, which will dramatically be increased over the next few years into powerful mathematical and computational modeling strategies may lead to the discovery of bionetworks-based breast cancer targets. These targets represent DNA changes in a nonlinear correlation relationship and can be used for the development of the next-generation of biomarkers and biological agents. The ultimate goal is to tailor the best responsive combination of drugs to individual patients on the basis of the networks prediction of clinical data, genetics-genomics data and their interactions.
Signaling pathways network prediction is also a very promising approach with therapeutic implications. Given the huge number of causal mutations as compared with the relatively small number of pathways deregulated by these mutated genes components of the pathways, screening techniques provide exciting opportunities. Indeed, new high-throughput analyses are being developed for screening breast cancer samples 70 for characterizing which signaling pathways, apart of well-known EGFR and VEGF, such as Wnt, Notch, TGF-beta, Hedgehog and others are deregulated in individual samples. 4, 35, 36, 54, 57, 74, 85, 86 Integrating all these data into molecular networks, we might link phenotypic drugs resistance and recurrence with deregulated signaling pathways networks for individual patients. This networks prediction can then be used for discovering novel robust assays for predicting recurrence risks and response or resistance, as well as a new generation signaling pathways networks-based biological agents.
Advanced-stage cancer Metastatic, recurrent or locally advanced unresectable cancer is an incurable disease. Development of new biologics tailored to novel biomarkers-based selection of responder individual patients at this final stage of disease has two major implications: first, to prolong survival of these patients. Second, even success of only few months OS benefit due to new agents, it may save the lives of many patients in the adjuvant setting. Indeed, clinical success of drugs at metastatic setting can usually be translated with drugs efficacy in the adjuvant setting of women with potentially curable stages I-III disease. As the largest number of both causal mutations (B100) and deregulated signaling pathways (B10), as well as the widest heterogeneity has been found among patients with stage IV breast cancer, and the highest grade of host immunity-tumor deregulation is met at this tumor stage, molecular networks of systems medicine might represent the most promising direction for future clinical success. Similar molecular networks predictive models using reverse engineering approaches, as described above in the adjuvant setting, but integrating clinical data of stage-IV patients could also here lead to the identification of crucial breast cancer targets. These bionetworks targets can then be used for the development of biomarkers and biologics.
Intellectual innovation
The landmark achievement of the first draft sequence of the human genome a decade ago raised excitement for a revolution in both personal genomics and medical practice. Now, 10 years later, every clinician knows that the genomics explosion has not, at least yet, translated into a day-to-day clinical practice. Distinguished scientists agree that the expectations for personal genomes-based diseases risk prediction and prevention and appropriate treatment of complex diseases, such as cancer for achieving cure were too high set. [87] [88] [89] [90] [91] [92] [93] [94] The leaders of the public and private efforts for the completion of human genome sequencing, Francis Collins and Craig Venter, both say sequencing explosions brought 'not much' in health. 88, 89 Collins emphasizes that personalized medicine passes through genotyping information 88 and Venter points out the importance of phenotype and the need to link clinical data with genetic variation. 89 Looking forward at the next decade, as the cost of full genome sequence drops rapidly, perhaps less than $1000 in the next few years, and the quality of genomics data increases, challenges should be overcome so that the astounding technological and intellectual advances will be applied into medical practice and improved health. 87 Yet, however, the way to reach faster personalized cancer prevention and treatment of breast, gastric and other major cancers has not been defined. Perhaps systems biology and medicine may lead to clinical success but beyond technology, inspired scientific intellectual should have the predominant role.
Conclusions
The explosion in sequencing technology provides now evidence that common diseases, such as cancer, responsible for high-mortality rates worldwide, are highly complex and heterogeneous.
A nearly linear genotype-phenotype relation is rare in human life explaining why a only few individuals benefit from the discovery of BRCA1/2 and CDH1 in prevention setting and trastuzumab for HER2 amplification in the treatment setting of breast cancer and gastric cancer.
At the end of the first post-genomic era and looking forward, the number of complete sequence of healthy and cancer personal genomes will dramatically be grown. But this genomic revolution providing a huge number of point mutations, genomic rearrangements and copy-number variants alone will only modestly improve oncological outcomes of patients with breast, gastric and other major cancers. It appears nearly essential to focus on how to link all these genotype data with clinical data of the phenotypic cancer diversity. Bionetworks modeling represents one of the most promising fields for understanding and predicting genotype-phenotype map. Although this is a new way towards personalized medicine, and perhaps beyond of the current state-of-the-art, technological advances and international networks of high intellectual scientists may lead to the next-generation, bionetworks-based development of robust biomarkers and drugs key cancer targets.
